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all patients) failed initially in the CNS.
Four additional patients subsequently
developed CNS metastases, for an over-
all CNS failure rate of 12 of 20 (relaps-
ing) patients, or 60%, representing al-
most 50% of all well-staged stage IIIA
and B NSCLC patients failing in the
CNS. (These failures were detected clin-
ically because routine post-study mag-
netic resonance imaging was not per-
formed). Thus, we hypothesize that the
low incidence of 8% CNS metastasis in
the Choong et al. study might in fact
suggest that temozolomide could poten-
tially have controlled microscopic CNS
disease in a proportion of patients.
Consistent with this supposition,
an earlier study reported by Adonizio et
al.3 using temozolomide as a single
agent produced similar results: five of
38 patients entered the study with
treated brain metastasis; two had CNS
progression and only one patient devel-
oped brain metastasis on study for an
incidence of 3%.
These results, taken collectively,
provide putative support for a well-
structured prospective clinical trial to
test the value of temozolomide for “pro-
phylaxis” (i.e., in reality, the treatment
of micrometastatic disease) of the CNS
in NSCLC. Such a study is now in its
final stages of development as a joint
project between the University of Wis-
consin Comprehensive Cancer Center,
the University of Texas Southwestern
Cancer Center, Dallas (Dr. Joan
Schiller), and the Fox Chase Cancer
Center, Philadelphia (Dr. Cory Langer).
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Reply to the Letter by
Robins et al.
To the Editor:
On behalf of the coauthors, we are
replying to the letter by Dr. Robins and
colleagues.
In our study evaluating temozolo-
mide and irinotecan as second-line
agents, we determined that the response
rate was only 9% with a short median
time to progression of 1.8 months. As a
result, the duration of treatment was
short (median two cycles or 6 weeks). In
this brief period, 67% of our subjects
had progressive disease including three
patients who developed new symptom-
atic brain metastasis. Because brain im-
aging was not required post-study, the
incidence of asymptomatic brain metas-
tasis is unknown but probably higher
than 8%.1 In addition, our trial was not
designed to specifically address the ef-
fect of temozolomide on brain metasta-
sis. We agree that the role of temozolo-
mide as prophylaxis against central
nervous system metastasis should be
evaluated in a large, well-designed pro-
spective trial.
Thank you very much for allow-
ing us to reply.
Nicholas W. Choong MD, and
Everett E. Vokes, MD
Section of Hematology-Oncology
University of Chicago Medical Center,
Chicago, Illinois
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Lung cancer frequently develops
in patients with idiopathic pulmonary
fibrosis (IPF).1 However, there is no
established or standardized chemother-
apy to date for advanced lung cancer
associated with IPF. Gefitinib, an oral
inhibitor of epidermal growth factor re-
ceptor (EGFR) tyrosine kinase domain,
is effective for selected patients with
advanced non-small cell lung cancer
(NSCLC).2 However, the incidence of
interstitial lung disease (ILD) caused by
gefitinib is as high as 5% in Japan, and
preexisting pulmonary fibrosis is con-
sidered to be a risk factor for developing
ILD.3,4 We report the case of a patient
with stage IV adenocarcinoma associ-
ated with IPF who was successfully
treated with gefitinib.
A 77-year-old man was admitted
to our hospital for the evaluation of a
mass lesion on chest radiograph. He
had smoked one pack of cigarettes
daily for 59 years. On examination,
fine crackles were heard at both lung
bases. A chest computed tomography
(CT) scan revealed a lobulated mass,
66  50 mm in diameter, in the right
upper lobe with enlargement of para-
tracheal, pretracheal, and subcarinal
lymph nodes (Figure 1A). In addition,
honeycombing was observed in the
lung base bilaterally (Figure 1B). A
diagnosis of adenocarcinoma was
made by transbronchial biopsy. Brain
CT disclosed a metastatic lesion, 5
mm in diameter, in the right parietal
lobe. The patient was diagnosed as
having stage IV (cT2N2M1) NSCLC
associated with IPF. At first, the brain
metastasis was treated by stereotactic
radiosurgery (gamma knife). Subse-
quently, the patient preferred gefitinib
for the first-line therapy to intravenous
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chemotherapy, and informed consent
was obtained.
After 3 weeks’ treatment with
gefitinib 250 mg/day, a chest CT scan
revealed substantial regression of both
the primary tumor and mediastinal
lymph node metastases without wors-
ening of IPF. This response lasted
for 7 months, and gefitinib was
discontinued.
The size of both the primary tu-
mor and the mediastinal lymph nodes
increased again after 3 months’ dis-
continuation of gefitinib. Re-treatment
with gefitinib was begun, and a signif-
icant response was observed within 2
weeks. Partial response continued for
5 months, but gefitinib was discontin-
ued because right hemiplegia resulting
from multiple brain metastases devel-
oped. After whole brain irradiation,
the patient received supportive care
alone and was referred to a hospital
near his home.
The prevalence of lung cancer in
IPF varies from 4.4% to 48.2% by the
type of studies.1 The pathogenesis of
lung cancer remains unclear, but recur-
rent injury and inflammation of IPF
would result in genetic alterations in
airway epithelial cells that predispose
patients to lung cancer.1
Chemotherapy for advanced lung
cancer associated with IPF is limited.
New chemotherapeutic agents such as
gemcitabine, irinotecan, paclitaxel, do-
cetaxel, and gefitinib can cause severe
pulmonary toxicity.1 The efficacy and
toxicity of these novel drugs for patients
with lung cancer associated with IPF
remain unknown, because most of the
prospective clinical studies do not in-
clude patients with co-morbid or poor
performance status.
Pretreatment clinical factors that
can predict gefitinib efficacy are: being
of East Asian origin, a non-smoker, a
woman, and having adenocarcinoma.2
Recent studies have shown that muta-
tions in the tyrosine kinase domain of
EGFR are associated with sensitivity to
gefitinib,5 although EGFR mutations of
tumor specimens of the patient were not
studied.
The reported incidence and mor-
tality of ILD caused by gefitinib is
approximately 2% to 5% in Japan.3,4
However, the incidence of ILD is re-
portedly less than 0.5% outside
Japan.1 Predicted risk factors for the
development of ILD are: preexisting
pulmonary fibrosis, poor performance
status, prior radiation therapy, and
Japanese ethnicity.3,4
Gefitinib can be administered to
patients with co-morbid conditions or
poor performance status. Because
treatment for advanced NSCLC asso-
ciated with IPF is limited, gefitinib
still remains one of the therapeutic
options for such patients if adminis-
tered under careful observation for
lung damage.
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FIGURE 1. Chest computed tomography scans of the patient (A) at the level of
aortic arch revealing a lobulated mass in the right upper lobe and paratracheal
lymph node enlargement and (B) at the level of lung base showing a honeycomb
appearance in both lungs.
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